Cargando…

Long-term use of adalimumab in the treatment of rheumatic diseases

Adalimumab, a fully humanized monoclonal antibody against tumor necrosis factor-alpha (TNFα), has been evaluated in various randomized placebo-controlled trials in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. In the short time frame of these tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Papagoras, Charalampos, Voulgari, Paraskevi V, Drosos, Alexandros A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074727/
https://www.ncbi.nlm.nih.gov/pubmed/27789981
_version_ 1782461761620803584
author Papagoras, Charalampos
Voulgari, Paraskevi V
Drosos, Alexandros A
author_facet Papagoras, Charalampos
Voulgari, Paraskevi V
Drosos, Alexandros A
author_sort Papagoras, Charalampos
collection PubMed
description Adalimumab, a fully humanized monoclonal antibody against tumor necrosis factor-alpha (TNFα), has been evaluated in various randomized placebo-controlled trials in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. In the short time frame of these trials adalimumab has been shown to be effective in reducing disease activity, slowing radiographic disease progression and improving patients’ quality of life, while at the same time demonstrating an acceptable safety profile. Furthermore, release of adalimumab on the market, prospective observational studies, as well as open-label extensions of the original double-blind trials have provided experience and data about the long-term efficacy and safety of the drug. Initial effectiveness, in terms of reducing disease activity, is sustained, while in most cases patients treated with adalimumab experienced a slower radiographic progression and consequently less disability and improved health-related quality-of-life outcomes. Moreover, long-standing treatment of thousands of patients with adalimumab outside the controlled context of clinical trials was not related to new safety signals, with the most common adverse events being respiratory infections. The most common serious adverse events seem to be tuberculosis reactivation, while a putative association with malignant lymphoma development is not yet proven. Besides, both of these adverse reactions pertain to the whole TNFα blocker group. In conclusion, adalimumab is a safe and effective option for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis.
format Online
Article
Text
id pubmed-5074727
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50747272016-10-27 Long-term use of adalimumab in the treatment of rheumatic diseases Papagoras, Charalampos Voulgari, Paraskevi V Drosos, Alexandros A Open Access Rheumatol Review Adalimumab, a fully humanized monoclonal antibody against tumor necrosis factor-alpha (TNFα), has been evaluated in various randomized placebo-controlled trials in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. In the short time frame of these trials adalimumab has been shown to be effective in reducing disease activity, slowing radiographic disease progression and improving patients’ quality of life, while at the same time demonstrating an acceptable safety profile. Furthermore, release of adalimumab on the market, prospective observational studies, as well as open-label extensions of the original double-blind trials have provided experience and data about the long-term efficacy and safety of the drug. Initial effectiveness, in terms of reducing disease activity, is sustained, while in most cases patients treated with adalimumab experienced a slower radiographic progression and consequently less disability and improved health-related quality-of-life outcomes. Moreover, long-standing treatment of thousands of patients with adalimumab outside the controlled context of clinical trials was not related to new safety signals, with the most common adverse events being respiratory infections. The most common serious adverse events seem to be tuberculosis reactivation, while a putative association with malignant lymphoma development is not yet proven. Besides, both of these adverse reactions pertain to the whole TNFα blocker group. In conclusion, adalimumab is a safe and effective option for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. Dove Medical Press 2009-05-18 /pmc/articles/PMC5074727/ /pubmed/27789981 Text en © 2009 Papagoras et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Papagoras, Charalampos
Voulgari, Paraskevi V
Drosos, Alexandros A
Long-term use of adalimumab in the treatment of rheumatic diseases
title Long-term use of adalimumab in the treatment of rheumatic diseases
title_full Long-term use of adalimumab in the treatment of rheumatic diseases
title_fullStr Long-term use of adalimumab in the treatment of rheumatic diseases
title_full_unstemmed Long-term use of adalimumab in the treatment of rheumatic diseases
title_short Long-term use of adalimumab in the treatment of rheumatic diseases
title_sort long-term use of adalimumab in the treatment of rheumatic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074727/
https://www.ncbi.nlm.nih.gov/pubmed/27789981
work_keys_str_mv AT papagorascharalampos longtermuseofadalimumabinthetreatmentofrheumaticdiseases
AT voulgariparaskeviv longtermuseofadalimumabinthetreatmentofrheumaticdiseases
AT drososalexandrosa longtermuseofadalimumabinthetreatmentofrheumaticdiseases